Advanced Life Sciences | ADLS - 500 Beiträge pro Seite
eröffnet am 04.06.09 18:02:21 von
neuester Beitrag 30.07.09 16:18:55 von
neuester Beitrag 30.07.09 16:18:55 von
Beiträge: 19
ID: 1.150.867
ID: 1.150.867
Aufrufe heute: 0
Gesamt: 1.885
Gesamt: 1.885
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 38 Minuten | 6062 | |
| vor 1 Stunde | 3794 | |
| vor 35 Minuten | 3141 | |
| vor 35 Minuten | 3079 | |
| vor 1 Stunde | 3017 | |
| heute 08:59 | 2984 | |
| vor 51 Minuten | 2141 | |
| vor 1 Stunde | 2120 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.768,76 | -0,68 | 220 | |||
| 2. | 2. | 154,74 | -4,17 | 130 | |||
| 3. | 3. | 6,3960 | -3,27 | 100 | |||
| 4. | 5. | 6,7420 | -3,96 | 73 | |||
| 5. | 4. | 2.363,87 | -0,73 | 63 | |||
| 6. | 20. | 23,970 | -2,68 | 49 | |||
| 7. | 8. | 7,5700 | -0,13 | 40 | |||
| 8. | 15. | 26,66 | -0,78 | 40 |
Feedback
-keine kauf oder verkaufsempfehlung - !!
Bin hier gerade zu 0,40 US$ rein
Homepage http://www.advancedlifesciences.com/
Mkt Cap: $ Mio 18,63
Outstanding: 45,99 Mio. Stk
Float: 43,09 Mio. Stk
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs in the areas of infection, cancer and respiratory disease. The Company’s lead product candidate, cethromycin, is a novel once-a-day antibiotic developed for the treatment of respiratory tract infections. The Company has three product candidates that are either in clinical development or approved to begin clinical development, as well as six additional candidates in preclinical development.
Company Factsheet: http://www.advancedlifesciences.com/download/ADLS_Company_Fa…
Press Room
Date Title
06/02/09 Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
05/29/09 Advanced Life Sciences Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Restanza(TM) (cethromycin)
05/12/09 Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook
Bin hier gerade zu 0,40 US$ rein
Homepage http://www.advancedlifesciences.com/
Mkt Cap: $ Mio 18,63
Outstanding: 45,99 Mio. Stk
Float: 43,09 Mio. Stk
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs in the areas of infection, cancer and respiratory disease. The Company’s lead product candidate, cethromycin, is a novel once-a-day antibiotic developed for the treatment of respiratory tract infections. The Company has three product candidates that are either in clinical development or approved to begin clinical development, as well as six additional candidates in preclinical development.
Company Factsheet: http://www.advancedlifesciences.com/download/ADLS_Company_Fa…
Press Room
Date Title
06/02/09 Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
05/29/09 Advanced Life Sciences Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Restanza(TM) (cethromycin)
05/12/09 Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook
Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
2009-06-02 17:41 ET - News Release
CHICAGO, June 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. announced today that the FDA's Anti-Infective Drugs Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). However, the committee voted that Restanza did not demonstrate efficacy in the treatment of CAP (3 positive, 11 negative, 1 abstaining).
(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
"We believe in Restanza's potential and remain committed to its development. We were particularly encouraged by the supportive comments of several members of the committee relative to their positive review of the safety profile of Restanza, the therapeutic need for more effective treatments for CAP and their interest in seeing the company pursue further development," said Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences. "As we have throughout the review process we will continue to work closely with the FDA as they complete their assessment of the Restanza new drug application (NDA)."
Although it is not binding, the Committee's recommendation will be considered by the FDA as it completes its review of Restanza's NDA in CAP. The FDA has established a Prescription Drugs User Fee Act (PDUFA) date of July 31, 2009 for the Restanza NDA.
Conference Call Details
Advanced Life Sciences will host a conference call and live webcast at 8:30 a.m. Eastern Time on Wednesday, June 3, 2009 to discuss the outcome of the AIDAC Review.
The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 866.713.8567 (domestic) or 617.597.5326 (international). The passcode for the conference call is 15573457. A replay of the conference call will be available until July 10, 2009. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 27483036. Investors are advised to dial into the call at least ten minutes prior to the call to register.
About Restanza
Restanza is a novel, once-a-day, oral antibiotic that is under review for approval by the FDA for the treatment of CAP. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin-, macrolide-, and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CAP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.
About Community Acquired Pneumonia (CAP)
CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. CAP affects 5.6 million patients in the United States each year, with 10 million physician visits and 2 million hospitalizations occurring annually.
Macrolides and penicillins are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer, respiratory diseases and biodefense. For more information, please visit us on the web at www.advancedlifesciences.com
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Advanced Life Sciences Holdings, Inc.
CONTACT: Joe Camp, of Advanced Life Sciences Holdings, Inc.,
+1-630-754-4352, jcamp@advancedlifesciences.com
Web site: http://www.advancedlifesciences.com/
2009-06-02 17:41 ET - News Release
CHICAGO, June 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. announced today that the FDA's Anti-Infective Drugs Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). However, the committee voted that Restanza did not demonstrate efficacy in the treatment of CAP (3 positive, 11 negative, 1 abstaining).
(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
"We believe in Restanza's potential and remain committed to its development. We were particularly encouraged by the supportive comments of several members of the committee relative to their positive review of the safety profile of Restanza, the therapeutic need for more effective treatments for CAP and their interest in seeing the company pursue further development," said Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences. "As we have throughout the review process we will continue to work closely with the FDA as they complete their assessment of the Restanza new drug application (NDA)."
Although it is not binding, the Committee's recommendation will be considered by the FDA as it completes its review of Restanza's NDA in CAP. The FDA has established a Prescription Drugs User Fee Act (PDUFA) date of July 31, 2009 for the Restanza NDA.
Conference Call Details
Advanced Life Sciences will host a conference call and live webcast at 8:30 a.m. Eastern Time on Wednesday, June 3, 2009 to discuss the outcome of the AIDAC Review.
The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 866.713.8567 (domestic) or 617.597.5326 (international). The passcode for the conference call is 15573457. A replay of the conference call will be available until July 10, 2009. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 27483036. Investors are advised to dial into the call at least ten minutes prior to the call to register.
About Restanza
Restanza is a novel, once-a-day, oral antibiotic that is under review for approval by the FDA for the treatment of CAP. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin-, macrolide-, and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CAP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.
About Community Acquired Pneumonia (CAP)
CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. CAP affects 5.6 million patients in the United States each year, with 10 million physician visits and 2 million hospitalizations occurring annually.
Macrolides and penicillins are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer, respiratory diseases and biodefense. For more information, please visit us on the web at www.advancedlifesciences.com
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Advanced Life Sciences Holdings, Inc.
CONTACT: Joe Camp, of Advanced Life Sciences Holdings, Inc.,
+1-630-754-4352, jcamp@advancedlifesciences.com
Web site: http://www.advancedlifesciences.com/
ADLS hat kein cash und die chancen auf Zulassung sind gleich 0 !
Und warum bist du eingestiegen ??
Und warum bist du eingestiegen ??
Antwort auf Beitrag Nr.: 37.321.767 von BrauchGeld am 04.06.09 18:11:04
zum zocken!
5 bis 10% reichen mir
zum zocken!
5 bis 10% reichen mir
Trading Spotlight
0,42 $ TH +7,69%
Bin erstmal wieder raus zu 0,42$
5% nach einem tag haben mir hier gereicht
5% nach einem tag haben mir hier gereicht
Antwort auf Beitrag Nr.: 37.321.767 von BrauchGeld am 04.06.09 18:11:04
ADLS hat kein cash und die chancen auf Zulassung sind gleich 0 !
Na und?
Jetzt schon von 0,40 auf 0,44 US$ seit deinem Posting. Bin leider schon raus.
ADLS hat kein cash und die chancen auf Zulassung sind gleich 0 !
Na und?
Jetzt schon von 0,40 auf 0,44 US$ seit deinem Posting. Bin leider schon raus.
Last Price (USD)
$ 0.47
Change
▲ 0.05 (11.90%)
Bid 0.47
Ask 0.48
Volume 1,637,141
Day's Range 0.41 - 0.48
$ 0.47
Change
▲ 0.05 (11.90%)
Bid 0.47
Ask 0.48
Volume 1,637,141
Day's Range 0.41 - 0.48
Hab ja geschrieben das ich zu 0.40 rein bin und zu 0.42 usd raus.
jetzt stehen wir bei 0,47 usd...
jetzt stehen wir bei 0,47 usd...
0,52$
Thread-Eröffnung war bei 0,40 $
Glückwunsch wer noch dabei ist
Thread-Eröffnung war bei 0,40 $
Glückwunsch wer noch dabei ist
Schluss heute auf 0,57 US$ 
und ich bin zu 0,42 raus....
und ich bin zu 0,42 raus....
0,66 $
0,75$
Thread Eröffnung war bei 0,40$
Thread Eröffnung war bei 0,40$
Nächster Zug!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 220 | ||
| 130 | ||
| 100 | ||
| 73 | ||
| 63 | ||
| 49 | ||
| 40 | ||
| 40 | ||
| 38 | ||
| 34 |
